ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01697527)
Timeline
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02650986 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02775292 | Phase 1 | Jan 3, 2017 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT02070406 | Phase 1 | Jul 1, 2014 | National Cancer Institute (NCI), University of California, Los Angeles |
| NCT01697527 | Phase 2 | Nov 1, 2012 | University of California, Los Angeles |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2014 |
| University of California, Los Angeles | Academic/Hospital | 3 | 3 | 2 | 2012 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1